According to Zhitong Finance App, Quanxin Bio-B (02509.HK) announced that recently, the long-acting dual-antibody QX027N injection independently developed by the company obtained implied clinical trial licenses (acceptance numbers: CXSL2600561, CXSL2600560) from the Drug Evaluation Center of the China National Drug Administration, and is intended to be used to treat chronic obstructive pulmonary disease (COPD) and chronic rhinosinusitis with sinus polyps (CRSwnP), respectively. This approval was given to QX027N for two new respiratory related indications after atopic dermatitis (AD) and asthma. The company will accelerate the pace of clinical development of this drug candidate and continue to consolidate its leading edge in related fields.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.